Tailored vaccines targeting immune responses for better protection against diseases like HIV and influenza
DC-subset-tailored vaccines
This study is looking at how certain immune cells help vaccines work better to create strong and lasting protection against diseases like HIV and the flu, so we can develop improved vaccines that keep you healthier for longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10843081 on NIH RePORTER |
What this research studies
This research investigates how specific immune cells, called dendritic cells, influence the effectiveness of vaccines in generating long-lasting antibody responses. By focusing on the role of different dendritic cell populations, the research aims to develop vaccines that are tailored to enhance immune responses against diseases such as HIV and influenza. The approach includes understanding how these cells interact with B cells and how varying the amount of vaccine antigen can optimize these interactions. Patients may benefit from improved vaccine strategies that provide better protection against these infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk for HIV or influenza, particularly those who may not respond well to current vaccines.
Not a fit: Patients who are not at risk for HIV or influenza or those who have already achieved effective immunity through existing vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide long-lasting immunity against HIV and influenza.
How similar studies have performed: Other research has shown promise in enhancing vaccine responses by targeting specific immune cells, suggesting that this approach could be effective.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Igyarto, Botond Z — Thomas Jefferson University
- Study coordinator: Igyarto, Botond Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.